Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 2/20 | 0.92 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.92 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.92 |
| ▸ | RELA | Q04206 | 1/20 | 0.92 |
| ▸ | PPARG | P37231 | 2/20 | 0.68 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.68 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.58 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.55 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1480564 | 0.96 | FPR2 (1.00) | FPR2NFKB1NFKB2RELAPPARG | |
| SCHEMBL1692159 | 0.96 | FPR2 (1.00) | FPR2NFKB1NFKB2RELAPPARG | |
| SCHEMBL3299698 | 0.96 | FPR2 (1.00) | FPR2NFKB1NFKB2RELAPPARG | |
| Lipoxin A4 SCHEMBL19668574 | 0.96 | FPR2 (1.00) | FPR2NFKB1NFKB2RELAPPARG | |
| Lipoxin A4 SCHEMBL8743448 | 0.96 | FPR2 (1.00) | FPR2NFKB1NFKB2RELAPPARG | |
| Lipoxin A4 SCHEMBL3302874 | 0.96 | FPR2 (1.00) | FPR2NFKB1NFKB2RELAPPARG | |
| Lipoxin A4 SCHEMBL1691709 | 0.96 | FPR2 (1.00) | FPR2NFKB1NFKB2RELAPPARG | |
| Lipoxin A4 SCHEMBL3408493 | 0.96 | FPR2 (1.00) | FPR2NFKB1NFKB2RELAPPARG | |
| SCHEMBL12102087 | 0.96 | FPR2 (1.00) | FPR2NFKB1NFKB2RELAPPARG | |
| SCHEMBL2346223 | 0.96 | FPR2 (1.00) | FPR2NFKB1NFKB2RELAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017083167-A1 | TOPICAL FORMULATIONS AND USES THEREOF | OCULAR TECHNOLOGIES SARL (CH) | 2017-05-18 | — | — | WO | disclosed |
| US-20160256521-A1 | TOPICAL FORMULATIONS AND USES THEREOF | OCULAR TECHNOLOGIES SARL (CH) | 2016-09-08 | — | — | US | disclosed |
| US-20160256521-A1 | TOPICAL FORMULATIONS AND USES THEREOF | OCULAR TECHNOLOGIES SARL (CH) | 2016-09-08 | — | — | US | disclosed |
| US-9315447-B2 | Compositions and methods for the treatment of inflammation | A.T. Resolve Sarl (CH) | 2016-04-19 | — | — | US | disclosed |
| US-9315447-B2 | Compositions and methods for the treatment of inflammation | A.T. Resolve Sarl (CH) | 2016-04-19 | — | — | US | disclosed |
| EP-2419399-B1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION | C T RESOLVE SARL (CH) | 2016-03-23 | — | — | EP | disclosed |
| US-20150165048-A1 | TOPICAL FORMULATIONS AND USES THEREOF | SUN PHARMA GLOBAL FZE (AE) | 2015-06-18 | — | — | US | disclosed |
| US-20150165048-A1 | TOPICAL FORMULATIONS AND USES THEREOF | SUN PHARMA GLOBAL FZE (AE) | 2015-06-18 | — | — | US | disclosed |
| US-20140275247-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION | A.T. Resolve Sarl (CH) | 2014-09-18 | — | — | US | disclosed |
| US-20140275247-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION | A.T. Resolve Sarl (CH) | 2014-09-18 | — | — | US | disclosed |
| US-20080161275-A1 | Compositions and methods for the treatment of inflammatory disease | RESOLVYX PHARMACEUTICALS, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20080161274-A1 | Compounds and methods for inhibition of bone loss | RESOLVYX PHARMACEUTICALS, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20080161275-A1 | Compositions and methods for the treatment of inflammatory disease | RESOLVYX PHARMACEUTICALS, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20080161274-A1 | Compounds and methods for inhibition of bone loss | RESOLVYX PHARMACEUTICALS, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| WO-2008070129-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASE | RESOLVYX PHARMACEUTICALS, INC. (US) | 2008-06-12 | — | — | WO | disclosed |
| WO-2008057283-A2 | USE OF RESOLVINS FOR INHIBITION OF BONE LOSS | RESOLVYX PHARMACEUTICALS, INC. (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008011085-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUCOSITIS | RESOLVYX PHARMACEUTICALS, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| WO-2007127377-A2 | COMBINATIONS COMPRISING OMEGA-3 FATTY ACID COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | RESOLVYX PHARMACEUTICALS, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| US-20070254897-A1 | Compositions and methods for the treatment of cardiovascular disease | RESOLVYX PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254897-A1 | Compositions and methods for the treatment of cardiovascular disease | RESOLVYX PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254897-A1 | Compositions and methods for the treatment of cardiovascular disease | ALOX15B, ALOX5, ALOX15 | FPR2 289/4885NFKB1 1429/4885NFKB2 2306/4885 |
| US-20080161275-A1 | Compositions and methods for the treatment of inflammatory disease | ALOX15B, ALOX12, ALOX15 | FPR2 42/4885NFKB1 323/4885NFKB2 382/4885 |
| US-20150165048-A1 | TOPICAL FORMULATIONS AND USES THEREOF | LIPA, MGLL, LIPC | FPR2 229/4885NFKB1 230/4885NFKB2 254/4885 |
| US-20080161274-A1 | Compounds and methods for inhibition of bone loss | ALOX15B, ALOX5, ALOX12 | FPR2 110/4885NFKB1 73/4885NFKB2 74/4885 |
| US-20140275247-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION | ALOX15B, ALOX5, ALOX12 | FPR2 22/4885NFKB1 850/4885NFKB2 942/4885 |
| US-20160256521-A1 | TOPICAL FORMULATIONS AND USES THEREOF | LIPA, MGLL, LIPC | FPR2 229/4885NFKB1 230/4885NFKB2 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.